Ingrid Glurich

Summary

Affiliation: Marshfield Clinic
Country: USA

Publications

  1. pmc Lack of evidence of WNT3A as a candidate gene for congenital vertebral malformations
    Nader Ghebranious
    University of Wisconsin Medical School, Madison, Wisconsin, USA and Geriatrics Research, Education, and Clinical Center, William S, Middleton Veterans Administration Medical Center, Madison, Wisconsin, USA
    Scoliosis 2:13. 2007
  2. doi request reprint Understanding the pharmacogenetic approach to warfarin dosing
    Ingrid Glurich
    Office of Scientific Writing and Publications, Marshfield Clinic Research Foundation, Marshfield, WI, USA
    Heart Fail Rev 15:239-48. 2010
  3. pmc Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses
    James K Burmester
    Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, WI 54449, USA
    Clin Med Res 9:119-24. 2011
  4. pmc A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data
    Michael A Hillman
    Center for Human Genetics, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI 54449, USA
    Clin Med Res 3:137-45. 2005
  5. doi request reprint A missense T (Brachyury) mutation contributes to vertebral malformations
    Nader Ghebranious
    Molecular Diagnostic Research Laboratory, Marshfield Clinic, Marshfield, Wisconsin 54449, USA
    J Bone Miner Res 23:1576-83. 2008
  6. pmc Evaluation of genetic factors for warfarin dose prediction
    Michael D Caldwell
    Center for Human Genetics, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI 54449, USA
    Clin Med Res 5:8-16. 2007
  7. ncbi request reprint DLL3 as a candidate gene for vertebral malformations
    Philip F Giampietro
    Department of Medical Genetic Services, Marshfield Clinic, Marshfield, Wisconsin 54449, USA
    Am J Med Genet A 140:2447-53. 2006
  8. ncbi request reprint Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype
    Michael A Hillman
    Department of Care Management, Marshfield Clinic, Marshfield, Wisconsin, USA
    Pharmacogenetics 14:539-47. 2004
  9. pmc CYP4F2 genetic variant alters required warfarin dose
    Michael D Caldwell
    Department of Surgery, Marshfield Clinic, Marshfield, WI, USA
    Blood 111:4106-12. 2008
  10. pmc Tamoxifen-induced venothromboembolic events: exploring validation of putative genetic association
    Ingrid Glurich
    Office of Scientific Writing and Publication, Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA
    Clin Med Res 11:16-25. 2013

Collaborators

Detail Information

Publications18

  1. pmc Lack of evidence of WNT3A as a candidate gene for congenital vertebral malformations
    Nader Ghebranious
    University of Wisconsin Medical School, Madison, Wisconsin, USA and Geriatrics Research, Education, and Clinical Center, William S, Middleton Veterans Administration Medical Center, Madison, Wisconsin, USA
    Scoliosis 2:13. 2007
    ..We hypothesized that WNT3A mutations might account for a subset of congenital vertebral malformations...
  2. doi request reprint Understanding the pharmacogenetic approach to warfarin dosing
    Ingrid Glurich
    Office of Scientific Writing and Publications, Marshfield Clinic Research Foundation, Marshfield, WI, USA
    Heart Fail Rev 15:239-48. 2010
    ..Finally, unresolved issues in improving clinical care of warfarin patients and future directions are provided...
  3. pmc Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses
    James K Burmester
    Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, WI 54449, USA
    Clin Med Res 9:119-24. 2011
    ..However, the most advanced regression models using personal, clinical, and genetic factors to predict individual stable dose account for only 50% to 60% of the observed variability in stable therapeutic dose in Caucasians...
  4. pmc A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data
    Michael A Hillman
    Center for Human Genetics, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI 54449, USA
    Clin Med Res 3:137-45. 2005
    ..The feasibility of prospective CYP2C9 model-based warfarin dosing has not yet been assessed...
  5. doi request reprint A missense T (Brachyury) mutation contributes to vertebral malformations
    Nader Ghebranious
    Molecular Diagnostic Research Laboratory, Marshfield Clinic, Marshfield, Wisconsin 54449, USA
    J Bone Miner Res 23:1576-83. 2008
    ..TBX6 mutations do not seem to be associated with CVM. We hypothesize that epistatic interactions between T and other developmental genes and the environment modulate the phenotypic consequences of T variants...
  6. pmc Evaluation of genetic factors for warfarin dose prediction
    Michael D Caldwell
    Center for Human Genetics, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI 54449, USA
    Clin Med Res 5:8-16. 2007
    ..To ultimately improve dosing of warfarin, we evaluated models for stable maintenance dose that incorporated both clinical and genetic factors...
  7. ncbi request reprint DLL3 as a candidate gene for vertebral malformations
    Philip F Giampietro
    Department of Medical Genetic Services, Marshfield Clinic, Marshfield, Wisconsin 54449, USA
    Am J Med Genet A 140:2447-53. 2006
    ....
  8. ncbi request reprint Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype
    Michael A Hillman
    Department of Care Management, Marshfield Clinic, Marshfield, Wisconsin, USA
    Pharmacogenetics 14:539-47. 2004
    ..7% of all dosing variability according to multiple regression. These results will help strengthen the mathematical models that are currently being developed for prospective gene-based warfarin dosing...
  9. pmc CYP4F2 genetic variant alters required warfarin dose
    Michael D Caldwell
    Department of Surgery, Marshfield Clinic, Marshfield, WI, USA
    Blood 111:4106-12. 2008
    ..Genetic variation of CYP4F2 was associated with a clinically relevant effect on warfarin requirement...
  10. pmc Tamoxifen-induced venothromboembolic events: exploring validation of putative genetic association
    Ingrid Glurich
    Office of Scientific Writing and Publication, Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA
    Clin Med Res 11:16-25. 2013
    ..A pilot study to examine accrual rates, efficiency of data capture approaches, study design and genotyping capacity for a future genetic validation study was undertaken...
  11. doi request reprint Progress in the understanding of the genetic etiology of vertebral segmentation disorders in humans
    Philip F Giampietro
    Department of Medical Genetic Services, Marshfield Clinic, 1000 North Oak Avenue, Marshfield, WI 54449, USA
    Ann N Y Acad Sci 1151:38-67. 2009
    ....
  12. pmc A pilot study of gene/gene and gene/environment interactions in Alzheimer disease
    Nader Ghebranious
    Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, WI 54449, USA
    Clin Med Res 9:17-25. 2011
    ..The purpose of this pilot study was to explore gene/gene and gene/environment associations in AD and to obtain data for sample size estimates for larger, more definitive studies of AD...
  13. pmc Applying case definition criteria to irritable bowel syndrome
    Steven H Yale
    Department of Internal Medicine, Marshfield Clinic, 1000 North Oak Avenue, Marshfield, Wisconsin 54449, USA
    Clin Med Res 6:9-16. 2008
    ..We sought to identify and validate cases of IBS based on the Manning, Rome I and Rome II diagnostic criteria in a rural practice setting...
  14. pmc Does CALU SNP rs1043550 Contribute Variability to Therapeutic Warfarin Dosing Requirements?
    Ingrid Glurich
    Corresponding Author Ingrid Glurich, PhD Marshfield Clinic Research Foundation 1000 North Oak Avenue Marshfield, WI 54449
    Clin Med Res 11:73-9. 2013
    ....
  15. ncbi request reprint Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9
    Steven H Yale
    Department of Internal Medicine, Marshfield Clinic, Marshfield, WI 54449, USA
    J Altern Complement Med 11:433-9. 2005
    ....
  16. ncbi request reprint Evaluation of SLC35A3 as a candidate gene for human vertebral malformations
    Nader Ghebranious
    Molecular Diagnostics Genotyping Laboratory, Marshfield Clinic, Marshfield, Wisconsin, USA
    Am J Med Genet A 140:1346-8. 2006
  17. doi request reprint Predicting atrial fibrillation and flutter using electronic health records
    Shreyas Karnik
    Biomedical Informatics Research Center, Marshfield Clinic Research Foundation, Marshfield Clinic, 1000 North Oak Avenue, Marshfield, WI 54449, USA
    Conf Proc IEEE Eng Med Biol Soc 2012:5562-5. 2012
    ..The combination of textual and coded data achieved comparable performance. The study results attest to the relative merit of utilizing textual data to complement the use of coded data for disease onset prediction modeling...
  18. pmc Serologic testing in connective tissue diseases
    Dana E Habash-Bseiso
    Department of Internal Medicine, Marshfield Clinic, Marshfield, WI 54449, USA
    Clin Med Res 3:190-3. 2005